Skip to content

Medical emergency? What to do

Smoking Belies Milder Disease but Worse Prognosis for IPF Patients

3-RXPublished January 15, 20083 min read

Key points

  • Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London.
  • The study appears in the second issue for January of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
  • The investigators studied the medical records of 249 patients with IPF, and analyzed the extent and severity of their disease, smoking history and survival.
  • Using the composite physiologic index (CPI), an index of disease severity that takes into account lung function and diffusion capacity as well as the confounding functional effects of concurrent emphysema, they found that survival was better in non-smokers than in the two smoking groups.

Smokers and ex-smokers with idiopathic pulmonary fibrosis (IPF), an untreatable progressive lung disease that usually leads to death within a few years of diagnosis, have a worse prognosis than non-smokers, according to research from London.

Previous research had counter-intuitively suggested that current smokers with IPF might live longer than ex-smokers, but the new study establishes that the data likely reflected a healthy smoker effect.

The study appears in the second issue for January of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

“Smoking is associated with a higher mortality in IPF, and an earlier finding, suggesting the contrary, was almost certainly due to the fact that smokers tend to stop smoking when disease becomes more severe—and so current smoking is linked to milder disease,” said Athol U. Wells, M.D., of the Interstitial Lung Disease Unit at the Royal Brompton Hospital in London, who headed the research.

The investigators studied the medical records of 249 patients with IPF, and analyzed the extent and severity of their disease, smoking history and survival. Their initial findings, unadjusted for disease severity, were similar to the earlier study— namely that smokers had longer survival times than ex-smokers. But when they adjusted their data to reflect the extent and severity of the disease at presentation, their findings shed a new light on the previous finding.

“We established that current smokers live longer, but this is mostly because they have much milder disease. Clearly, many patients stop smoking precisely because their disease is getting worse. This is the ‘healthy smoker’ effect: that current smoking is a marker for milder disease because advancing disease causes smoking cessation,” said Dr. Wells. “Symptomatic patients with more severe disease may be more likely to stop smoking for perceived health reasons. It can, therefore, be argued that current smoking might be a marker of less severe disease, associated with better survival.”

Using the composite physiologic index (CPI), an index of disease severity that takes into account lung function and diffusion capacity as well as the confounding functional effects of concurrent emphysema, they found that survival was better in non-smokers than in the two smoking groups.

“We speculate as to whether this reflects disease co-morbidity—that is, excess mortality from non-pulmonary disease ascribable to smoking— or an effect of smoking in driving progression of lung disease,” said Dr. Wells.

The researchers have several ongoing studies to determine the precise linkage between smoking damage such as smoking-related emphysema, IPF and other forms of fibrotic lung disease.

“The next step is to pursue the idea that mechanisms linked to smoking cause progression of pulmonary fibrosis,” says Dr. Wells. “If we can then understand these mechanisms better, this may give us new treatment options.”

Source: American Thoracic Society (ATS)

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.